RICHMOND, Calif., Dec. 7, 2010 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today the presentation of preclinical data that demonstrate the ability to permanently correct a disease gene in an animal using systemic delivery of zinc finger nucleases (ZFNs). The presentation was one of four made by Sangamo's collaborators at the 52nd Annual Meeting of the American Society of Hematology (ASH), which is being held in Orlando, Florida.
Abst.# 647 "Manipulating Higher Order Chromatin Structure of the Beta-Globin Locus by Targeted Tethering of a 'looping' Factor" Oral Session: Thalassemia and Globin Gene Regulation: Regulation of Globin Gene Expression
These data demonstrate the use of zinc finger DNA-binding proteins (ZFPs) as a tool to dissect the role of the physical structure of a chromosome in gene regulation.
Abst.# 3764 "Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia" Poster Session: Gene Therapy and Transfer: Poster II
The study describes a ZFN-based method for improving the potency, specificity and safety of T-cell immunotherapy approaches to cancer immunotherapy.
Abst.# 3766 "HLA and TCR Knockout by Zinc Finger Nucleases: Toward "off-the-Shelf" Allogeneic T-Cell Therapy for CD19+ Malignancies" Poster Session: Gene Therapy and Transfer: Poster II
These data provide proof of concept for the use of ZFN-based gene modification to develop 'off-the-shelf' cell-based immunotherapies to treat individuals of any HLA type.
Abst.# LBA-5 "Phenotypic Correction of a Mouse Model of Hemophilia B by In Vivo Genetic Correction of the F9 Gene" Oral Session: Late-Breaking Abstracts Session
"These data represent important progress in the advancement of systemic ZFN-based therapeutics towards clinical developm
|SOURCE Sangamo BioSciences, Inc.|
Copyright©2010 PR Newswire.
All rights reserved